This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Oncology, Other  • Statistics and Research Methods  • Randomized Controlled Trial  • Drug Therapy  • Drug Therapy, Other  • Genetics  • Genetics, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Better Trial Design Could Boost Success Rate

Tracy Hampton, PhD

JAMA. 2006;296:1951-1952.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Chicago—Scientists have long known that unlocking the mysteries of the human genome would lead to better diagnostics and therapies for a variety of diseases, but they were quick to note that the completion of its sequencing 3 years ago was just the first step toward tailoring medical care to individuals. Now, though, experts are concerned that progress is lagging and that current research strategies and designs are not up to tackling the challenges ahead.

"Patients have said that we’ve heard about personalized molecular medicine for the last 5 to 10 years," said Gordon Mills, MD, PhD, of the University of Texas M.D. Anderson Cancer Center, in Houston. "We're going to need to move forward more quickly." At the American Association for Cancer Research's recent conference on Molecular Diagnostics in Cancer Therapeutic Development, Mills and others in academia, industry, and government discussed hurdles that stand in the . . . [Full Text of this Article]

DRUG FAILURES



CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?